Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Sees Significant Increase in Short Interest

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 371,600 shares, a growth of 6.0% from the September 15th total of 350,500 shares. Based on an average daily trading volume, of 214,600 shares, the short-interest ratio is currently 1.7 days. Approximately 2.9% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a report on Saturday, October 12th. They issued a “hold” rating on the stock.

Eagle Pharmaceuticals Stock Performance

NASDAQ:EGRX opened at $0.65 on Friday. The stock’s 50 day moving average price is $3.49 and its 200 day moving average price is $4.26. Eagle Pharmaceuticals has a 52 week low of $0.10 and a 52 week high of $14.78. The company has a market capitalization of $8.44 million, a P/E ratio of 0.55 and a beta of 0.51.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC increased its holdings in Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 2,861 shares during the last quarter. Creative Planning acquired a new position in Eagle Pharmaceuticals in the third quarter worth approximately $59,000. Mackenzie Financial Corp acquired a new position in Eagle Pharmaceuticals in the second quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $65,000. Finally, Fidelis Capital Partners LLC acquired a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $71,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.